| 44 |
Tailoring Antiplatelet Therapy Is Still Necessary? |
Ki-Bae Seung |
May. 15. 12 |
| 43 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
Jul. 22. 09 |
| 42 |
Tailoring Treatment to Risk in Antiplatelet Therapy |
Alexandra J. Lansky |
Jul. 22. 09 |
| 41 |
What Is the Optimal Duration of DAPT Following DES Treatment? |
David E. Kandzari |
Jul. 22. 09 |
| 40 |
Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib |
Roxana Mehran |
Jul. 22. 09 |
| 39 |
Does the Efficacy of Bivalirudin During PCI Depend on Clopidogrel Pretreatment? |
Matthew Price |
Jul. 22. 09 |
| 38 |
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel) |
Gregg W. Stone |
Jul. 22. 09 |
| 37 |
New Paradigms in Treatment of ACS/AMI |
Roxana Mehran |
Jul. 22. 09 |
| 36 |
Not So Fast: The Data Are Circumstantial |
Ron Waksman |
Jul. 21. 09 |
| 35 |
Definitely: The Data Are Strong |
Matthew Price |
Jul. 21. 09 |
